Ligand Pharmaceuticals Inc (LGND) stock
LGNDNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as LGNDZ, LGNXZ, LGNYZ, LGNZZ
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 6/30433% above fair value
$293.81−7.90 (-2.62%)
Close on Nov 17, 2026Market cap $5.88BP/E 128.3Yield –
Ligand Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Ligand Pharmaceuticals's R&D Expenses for the twelve months ending Sep 30, 2026 was $23.09M, down 71.9% year over year. For fiscal 2025 it was $81.18M, up 278.9% from the year before. Over ten years it grew 22.1% a year on average. The highest annual figure on record is $81.18M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $81.18M | +278.9% |
| FY2024 | Dec 31, 2024 | $21.43M | -12.7% |
| FY2023 | Dec 31, 2023 | $24.54M | -32.0% |
| FY2022 | Dec 31, 2022 | $36.08M | +12.4% |
| FY2021 | Dec 31, 2021 | $32.11M | -20.7% |
| FY2020 | Dec 31, 2020 | $40.50M | -27.6% |
| FY2019 | Dec 31, 2019 | $55.91M | +100.7% |
| FY2018 | Dec 31, 2018 | $27.86M | +3.6% |
| FY2017 | Dec 31, 2017 | $26.89M | +26.7% |
| FY2016 | Dec 31, 2016 | $21.22M | +92.8% |
| FY2015 | Dec 31, 2015 | $11.01M | +12.9% |
| FY2014 | Dec 31, 2014 | $9.75M | +5.1% |
| FY2013 | Dec 31, 2013 | $9.27M | -14.1% |
| FY2012 | Dec 31, 2012 | $10.79M | +4.8% |
| FY2011 | Dec 31, 2011 | $10.29M | -53.4% |
| FY2010 | Dec 31, 2010 | $22.07M | -44.7% |
| FY2009 | Dec 31, 2009 | $39.87M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $2.77M | -86.8% |
| Q2 FY2026 | Jun 30, 2026 | $14.67M | +123.4% |
| Q1 FY2026 | Mar 31, 2026 | $2.15M | -95.7% |
| Q4 FY2025 | Dec 31, 2025 | $3.51M | -20.7% |
| Q3 FY2025 | Sep 30, 2025 | $21.02M | +270.4% |
| Q2 FY2025 | Jun 30, 2025 | $6.57M | +22.7% |
| Q1 FY2025 | Mar 31, 2025 | $50.09M | +738.8% |
| Q4 FY2024 | Dec 31, 2024 | $4.43M | -19.4% |
| Q3 FY2024 | Sep 30, 2024 | $5.68M | +2.6% |
| Q2 FY2024 | Jun 30, 2024 | $5.35M | -21.9% |
| Q1 FY2024 | Mar 31, 2024 | $5.97M | -10.4% |
| Q4 FY2023 | Dec 31, 2023 | $5.49M | -40.3% |
| Q3 FY2023 | Sep 30, 2023 | $5.53M | -40.1% |
| Q2 FY2023 | Jun 30, 2023 | $6.85M | -19.1% |
| Q1 FY2023 | Mar 31, 2023 | $6.66M | -27.4% |
| Q4 FY2022 | Dec 31, 2022 | $9.20M | +12.9% |
| Q3 FY2022 | Sep 30, 2022 | $9.24M | +24.3% |
| Q2 FY2022 | Jun 30, 2022 | $8.47M | +13.2% |
| Q1 FY2022 | Mar 31, 2022 | $9.18M | +1.5% |
| Q4 FY2021 | Dec 31, 2021 | $8.15M | +169.1% |
| Q3 FY2021 | Sep 30, 2021 | $7.43M | -42.2% |
| Q2 FY2021 | Jun 30, 2021 | $7.48M | -41.2% |
| Q1 FY2021 | Mar 31, 2021 | $9.05M | -23.9% |
| Q4 FY2020 | Dec 31, 2020 | $3.03M | -83.8% |
| Q3 FY2020 | Sep 30, 2020 | $12.85M | -6.5% |
| Q2 FY2020 | Jun 30, 2020 | $12.73M | +4.2% |
| Q1 FY2020 | Mar 31, 2020 | $11.89M | +5.3% |
| Q4 FY2019 | Dec 31, 2019 | $18.66M | +111.1% |
| Q3 FY2019 | Sep 30, 2019 | $13.74M | +150.6% |
| Q2 FY2019 | Jun 30, 2019 | $12.21M | +99.1% |
| Q1 FY2019 | Mar 31, 2019 | $11.29M | +52.4% |
| Q4 FY2018 | Dec 31, 2018 | $8.84M | +2.4% |
| Q3 FY2018 | Sep 30, 2018 | $5.48M | +15.2% |
| Q2 FY2018 | Jun 30, 2018 | $6.14M | +27.2% |
| Q1 FY2018 | Mar 31, 2018 | $7.41M | -14.6% |
| Q4 FY2017 | Dec 31, 2017 | $8.63M | +34.7% |
| Q3 FY2017 | Sep 30, 2017 | $4.76M | – |
| Q2 FY2017 | Jun 30, 2017 | $4.82M | – |
| Q1 FY2017 | Mar 31, 2017 | $8.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $6.41M | – |
See a number that looks wrong?